Advagene Biopharma Co., Ltd. (TPEX:6709)
Taiwan · Delayed Price · Currency is TWD 25.90
+0.35 (1.37%)
May 29, 2026, 1:35 PM CST
Advagene Biopharma Market Cap
Advagene Biopharma has a market cap or net worth of 1.53 billion as of May 29, 2026. Its market cap has increased by 50.44% in one year.
Market Cap
1.53B
Enterprise Value
1.40B
Revenue
n/a
Ranking
n/a
PE Ratio
n/a
Stock Price
25.90
Market Cap Chart
Since November 29, 2018, Advagene Biopharma's market cap has increased from 1.16B to 1.53B, an increase of 32.21%. That is a compound annual growth rate of 3.79%.
Market Cap History
| Date | Market Cap | % Change |
|---|---|---|
| May 29, 2026 | 1.53B | -8.02% |
| Dec 31, 2025 | 1.67B | 36.50% |
| Dec 31, 2024 | 1.22B | -9.95% |
| Dec 29, 2023 | 1.36B | -8.36% |
| Dec 30, 2022 | 1.48B | -38.27% |
| Dec 30, 2021 | 2.40B | 63.31% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro |
| Dec 25, 2019 | Upgrade Pro | Upgrade Pro |
| Dec 28, 2018 | Upgrade Pro | Upgrade Pro |
| Nov 29, 2018 | Upgrade Pro | Upgrade Pro |
Market Capitalization
Market capitalization, also called net worth, is the total value of all of a company's outstanding shares. It is calculated by multiplying the stock price by the number of shares outstanding.
Formula: Market Cap = Stock Price * Shares Outstanding
Full DefinitionRelated Stocks
| Company | Market Cap |
|---|---|
| Greenyn Biotechnology | 1.81B |
| Synbio Tech | 1.72B |
| TaiRx | 1.68B |
| Anti-Microbial Savior BioteQ | 1.66B |
| Great Novel Therapeutics Biotech & Medicals | 1.64B |
| Bio Preventive Medicine | 1.49B |
| GenMont Biotech Incorporation | 1.43B |
| Andros Pharmaceuticals Co.,Ltd | 1.37B |